There are 15 belonging to HealthShares family of ETFs, which will release between now and March. They deal with companies investing in dermatology, infectious diseases, and enabling technologies to name a few. Trang Ho reports that all of these portfolios have been built on big pharma and big biotech.
State funds is another area that providers are beginning to focus on. However, the idea of investing in companies by state is questionable.
The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.